drugset / Trial / NCT00834704

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

NCT00834704

Phase 1 Completed 14 enrolled Halozyme Therapeutics
Non-randomizedSingle-groupOpen-label

Summary

Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.

Timeline

Start
2009-02
Primary completion
2012-06
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegvorhyaluronidase Alfa Protein / enzyme biologic Intravenous

Indications